Jingjing Feng

机构：University of Maryland, Baltimore, Cell Technology (China), Hal Technology (United States), Zhejiang Institute of Mechanical and Electrical Engineering, Zhejiang University · ORCID：0000-0002-1607-4499

发表论文 113 篇 · 总被引 1627 次 · h-index 22

代表论文

• Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial (2025 · Nature Medicine · 被引 63)
• Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (2025 · JAMA Oncology · 被引 30)
• Gut Microbiome and Immune System Crosstalk in Chronic Inflammatory Diseases: A Narrative Review of Mechanisms and Therapeutic Opportunities (2025 · Microorganisms · 被引 22)
• Tumor treating fields suppress tumor cell growth and induce immunogenic cell death biomarkers in biliary tract cancer cell lines (2025 · Scientific Reports · 被引 8)
• Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (2025 · Bone Marrow Transplantation · 被引 5)
• XGBoost-based model for predicting PICC occlusion risk in cancer patients: Insights from SHAP analysis (2025 · Alexandria Engineering Journal · 被引 5)